drugset / Trial / NCT03132324
A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the safety and tolerability, and the pharmacokinetic and biologic activity of INCB059872 in participants with sickle cell disease.
Timeline
- Start
- 2017-04-20
- Primary completion
- 2018-10-03
- Completion
- 2018-10-03
Outcome
Outcome not reported
Stopped (Business): “This study is terminated due to a business decision not to pursue INCB059782 in Sickle Cell Disease indication.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INCB059872 | Small molecule | 0.5 mg | Oral |
| Subject | INCB059872 | Small molecule | 1 mg | Oral |
| Subject | INCB059872 | Small molecule | 2 mg | Oral |